Across TCGA pan-cancer cohorts, FGF23 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FGF23 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher FGF23 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FGF23 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
LUSC, BRCA, and UCEC are the cancer types where FGF23 Mutation most reproducibly stratifies survival.